Haematopoietic development and leukaemia in Down Syndrome

Irene Roberts, Shai Izraeli

Research output: Contribution to journalArticlepeer-review


Children with constitutional trisomy 21 (cT21, Down Syndrome, DS) are at a higher risk for both myeloid and B-lymphoid leukaemias. The myeloid leukaemias are often preceded by a transient neonatal pre-leukaemic syndrome, Transient Abnormal Myelopoiesis (TAM). TAM is caused by cooperation between cT21 and acquired somatic N-terminal truncating mutations in the key haematopoietic transcription factor GATA1. These mutations, which are not leukaemogenic in the absence of cT21, are found in almost one-third of neonates with DS. Analysis of primary human fetal liver haematopoietic cells and of human embryonic stem cells demonstrates that cT21 itself substantially alters human fetal haematopoietic development. Consequently, many haematopoietic developmental defects are observed in neonates with DS even in the absence of TAM. Although studies in mouse models have suggested a pathogenic role of deregulated expression of several chromosome 21-encoded genes, their role in human leukaemogenesis remains unclear. As cT21 exists in all embryonic cells, the molecular basis of cT21-associated leukaemias probably reflects a complex interaction between deregulated gene expression in haematopoietic cells and the fetal haematopoietic microenvironment in DS.

Original languageEnglish
Pages (from-to)13-33
Number of pages21
JournalPediatric Hematology/Oncology and Immunopathology
Issue number3
StatePublished - 2015


  • Acute lymphoblastic leukaemia
  • Acute megakaryoblastic leukaemia
  • Down syndrome
  • GATA1
  • Transient abnormal myelopoiesis
  • Trisomy 21


Dive into the research topics of 'Haematopoietic development and leukaemia in Down Syndrome'. Together they form a unique fingerprint.

Cite this